Kevin Hrusovsky to Speak at Precision Medicine Leaders Summit’s Precision Oncology Conference
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Kevin Hrusovsky, will present at the Precision Medicine Leaders Summit's Precision Oncology Conference today at 3:15 p.m. EDT. His keynote, titled “Revolutionizing Cancer Treatment and Detection with Biomarkers,” will highlight advances in multiplex assays that enable the identification of multiple oncology biomarkers simultaneously. This technology allows for early cancer detection and enhances the efficacy of immuno-oncology treatments. For more details, visit www.quanterix.com.
- None.
- None.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President and Founder, Powering Precision Health (PPH), Kevin Hrusovsky, will speak today at the Precision Medicine Leaders Summit’s (PMLS) Precision Oncology Conference. Hrusovsky’s keynote presentation, “Revolutionizing Cancer Treatment and Detection with Biomarkers,” will take place at 3:15 p.m., EDT. To register for today’s event visit, https://www.engagez.net/pmls-precisiononcology.
During his presentation, Hrusovsky will discuss advances in highly sensitive multiplex assays, which are enabling researchers to identify and quantify multiple oncology biomarkers simultaneously. This insight paired with the unprecedented ability to see biomarkers in minute concentrations in the blood, as enabled by ultra-sensitive biomarker platforms, is creating new pathways for detecting cancer at its earliest stages. Hrusovsky’s keynote will also speak to the important role of biomarkers in improving the efficacy and safety of immuno-oncology-based treatments by empowering researchers to optimize dosing and minimize toxicity associated with severe side effects.
For more information on Quanterix, please visit www.quanterix.com.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
